Related Experiment Videos
[Treatment of diffuse membranous glomerulonephritis with a combination of anticoagulants and corticosteroids]
Insights
This study shows a novel combination therapy of anticoagulants and corticosteroids effectively treats diffuse membranous glomerulonephritis, achieving high remission rates in patients. The treatment offers a promising new approach for this kidney condition.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Context:
- Diffuse membranous glomerulonephritis (mG) is a significant cause of nephrotic syndrome.
- Current treatment options for mG have limitations and variable efficacy.
- There is a need for novel therapeutic strategies to improve patient outcomes.
Purpose:
- To evaluate the efficacy of an original therapeutic combination of anticoagulants (heparin and acenocoumarol) and corticosteroids in patients with diffuse membranous glomerulonephritis.
- To assess the remission rates and time to remission with this novel treatment regimen.
Summary:
- Eighteen patients with diffuse membranous glomerulonephritis received a combination therapy including intravenous heparin, followed by acenocoumarol, and oral prednisone.
- Treatment duration ranged from 7 to 60 months (average 18.8 months).
- Complete clinical-laboratory remission was achieved in 77.8% of patients, with partial remission in 16.7%.
Impact:
- The findings suggest that this unique combination therapy, alongside prolonged treatment and diligent follow-up, significantly improves outcomes for patients with diffuse membranous glomerulonephritis.
- This approach represents a potentially valuable therapeutic option for managing this kidney disease.
- The study highlights the synergistic effect of anticoagulants and corticosteroids in treating mG.
Abstract:
The results are reported from the administration of an original therapeutic combination, including anticoagulants (heparin and acenocoumarol) and corticosteroids to 18 patients with diffuse membranous glomerulonephritis. The anticoagulant treatment begins with heparin intravenously (30 000 U daily) and continues, after 1-2 months with acenocoumarol. The corticosteroids were applied with an initial dose of 60 mg prednison, with further gradual decrease. The treatment lasts from 7 to 60 months (18,8 months on the average). Complete clinical-laboratory remission was obtained in 14 patients (77,8%), and partial in 3 (16,7%). The remission develops 6 to 24 months (8,7 months on the average) after the initiation of the treatment. According to the author, the good therapeutic results are due to the original combination of anticoagulants with corticosteroids, not administered so far by other authors to membranous glomerulonephritis, to the rather long-term treatment and to the qualitative follow-up care.